AR-T immunotherapy has proved a powerful treatment option for patients with certain advanced blood cancers — but it can be very dangerous as well, causing severe and sometimes deadly inflammation in the brain.

Now, researchers are a step closer to figuring out why — and to identifying those patients most likely to suffer severe reactions.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.